AXGN Axogen, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 805928 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.3%
TTM net income YoY-1,422.3%
TTM EPS YoY-1,160.0%
Revenue 3-yr CAGR20.6%
Net income 3-yr CAGR—
Margins
Gross margin74.2%
Operating margin-5.2%
Net margin-12.0%
FCF margin8.3%
EBITDA margin-2.8%
Returns
ROE-10.3%
ROA-8.3%
ROIC (approx.)-7.1%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio12.02x
Interest coverage-5.72x
Cash quality & payout
Operating cash flow / net income-0.89x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $225.21M | $187.34M |
| Cost of revenue | $57.85M | $45.36M |
| Gross profit | $167.35M | $141.98M |
| R&D expense | $32.88M | $27.77M |
| SG&A expense | $44.58M | $39.04M |
| Operating income | -$7.85M | -$3.29M |
| Interest expense | $7.70M | $8.21M |
| Income tax | $0 | $0 |
| Net income | -$15.70M | -$9.96M |
| EBITDA | -$1.19M | $3.18M |
| EPS (basic) | -0.34 | -0.23 |
| EPS (diluted) | -0.34 | -0.23 |
| Weighted avg. shares (diluted) | 46.05M | 44.26M |
| Balance sheet | ||
| Cash & equivalents | $35.55M | $33.55M |
| Short-term investments | $5.98M | $5.93M |
| Receivables | $26.17M | $24.11M |
| Inventory | $42.37M | $33.18M |
| Current assets | $120.42M | $99.22M |
| PP&E, net | $81.78M | $84.67M |
| Intangibles | $6.75M | $5.58M |
| Total assets | $221.69M | $203.73M |
| Current liabilities | $23.56M | $30.61M |
| Long-term debt | $48.39M | $47.50M |
| Total debt | $48.39M | $47.50M |
| Total liabilities | $92.84M | $99.82M |
| Shareholders' equity | $128.85M | $103.91M |
| Net debt | $12.84M | $13.94M |
| Shares outstanding | 47.20M | 44.15M |
| Cash flow statement | ||
| Operating cash flow | $812,000 | $4.54M |
| Capital expenditure | $3.75M | $3.10M |
| Free cash flow | -$2.93M | $1.43M |
| Investing cash flow | -$5.32M | -$10.30M |
| Financing cash flow | $10.50M | $2.29M |
| Depreciation & amortization | $6.66M | $6.47M |
| Stock-based compensation | $30.11M | $15.91M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.